N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
N/A N=34 Psoriasis Microbiome and Phototherapy
Psoriasis
Primary: Cutaneous Microbiota Shannon's Alpha Diversity at Baseline — -0.05; 0.06; -0.06; 0.12 Shannon's index
Phase 1 N=24 A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Change in the Total Clinical Score From Baseline to Day 22 — -2.8; -1.9; -1.5; -1.8 units on a scale
Phase 4 N=1,013 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
N/A N=103 Improvement of Psoriasis Patients' Adherence to Topical Drugs
Psoriasis Vulgaris
Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale
Phase 3 N=30 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Number of Participants With Clinical Improvement of Target Lesions — 18 Participants
Phase 2 N=24 A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products
Psoriasis Vulgaris
Primary: Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1) — -1.60; -4.96; -3.04; -3.96 score on a scale — p=<0.001
Phase 2 N=71 CP-690-550 Ointment For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change
Phase 2 N=129 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495
Phase 2 N=81 Topical CP-690,550 For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change
Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale
Phase 3 N=130 Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
Psoriasis
Primary: Pruritus Intensity Visual Analogue Scale Score at Week 32 — 8.8; 27.1 Units on a scale — p=0.0055
Phase 3 N=442 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale — 99; 9 Participants — p=<0.0001
N/A N=660 Assessment of Long-Term Infliximab for Psoriasis (P05319)
Psoriasis
Primary: Number of Participants With a Psoriasis Area Sensitivity Index (PASI)-75 Response at Week 50 — 296 Participants
N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis
Nail Psoriasis
Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
Phase 2 N=68 AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
Psoriasis
Primary: Percentage of Participants Who Achieved Success in Physician's Global Assessment (PGA) of Disease Severity at Day 84 — 17.4; 13.6 percentage of participants
Phase 2 N=100 Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Chronic Plaque Psoriasis
Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores — -12.46; -13.35; -18.02; -4.18 scores on a scale
Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…
Phase 3 N=439 Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 — 108; 8 Participants — p=<0.0001
Phase 2 N=46 A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Safety and Tolerability of IMO-8400 Compared With Placebo — 6; 6; 6; 5 adverse events — p=0.06
Phase 3 N=174 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Psoriasis
Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
N/A N=246 Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Months 1, 3, 6, and 9 — 31.3; 52.8; 55.8; 57.5 percentage of participants
Phase 2 N=24 A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Change in Total Clinical Score From Baseline to Day 22 — -3.6; -3.7; -4.9; -1.3 units on a scale